ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated. If you have any questions, please contact Marianne Reed at mreed@ku.edu .

Show simple item record

dc.contributor.advisorPrisinzano, Thomas E
dc.contributor.authorVasiljevik, Tamara
dc.date.accessioned2016-10-11T15:40:05Z
dc.date.available2016-10-11T15:40:05Z
dc.date.issued2013-12-31
dc.date.submitted2013
dc.identifier.otherhttp://dissertations.umi.com/ku:13078
dc.identifier.urihttp://hdl.handle.net/1808/21629
dc.description.abstractAgents that exert their effects in the central nervous system are among the most important in medicinal practice. One in three Americans will have a disease affecting the nervous system in their lifetime exceeding $600 billion dollars per year in cost. Side effects, lack of efficacy, and lack of selectivity hamper their clinical use. Thus, additional agents need to be developed and new chemical tools are needed to further elucidate the mechanisms of CNS disorders. Salvinorin A, the main component of the hallucinogenic mint Salvia divinorum is a novel and potent ê opioid (KOP) receptor agonist that is the first naturally occurring opioid ligand that lacks a basic nitrogen atom. In efforts to attain a greater understating for the interatctions of the furan ring binding pocket within the KOP receptor, several modifications were made at the C-13 position of the salvinoirn A scaffold. Pharmacological evaluations of the synthesized analogues indicated that there is a prefferred orientation of the furan O-atom in that the cis alkene analogue (236) had a greater binding affinity than the trans alkene analogue (235). However, despite its similar binding affinity to that of salvinorin A the cis analogue showed to 34-fold less active than salvinorin A. It was also hypothesized that a combination of the salvinorin A scaffold with a similar terpene based family of marine natural products, namely the nakijiquinones, will alter the biological activity of salvinorin A and yield a useful biological probe. With this hypothesis in mind, several quinone containing salvinoirn A analogues were synthesized and upon pharmacological evaluation it was determined that these analogues did not exhibit any significant KOP receptor activity, indicative of a change in the biological activity of the salvinorin A scaffold. Furthermore, these analogues proved to be the first salvinorin A based analogues that exhibit antiproliferative activity. In the search for novel CNS biological probes, the aminoalkylindole class of synthetic cannabinoids was also investigated. Due to its cannabinoid 1 receptor (CB1R) antagonist activity, JWH-073-M4 was shown to be a valuable lead molecule. The hypothesis was that the design and synthesis of JWH-073-M4 based analogues would lead to compounds with dual CB1R antagonist/CB2R agonist activity that may have potential as alcohol abuse therapies. Upon in vitro pharmacological investigation, two analogues 461 and 444 were shown to have the most promise and were further subjected to in vivo pharmacological evaluation in animal models of alcohol abuse, namely ethanol self-administration and ethanol conditioned place preference. From these studies it was determined that analogues 461 and 444 exhibit dual CB1R antagonist/CB2R agonist activity and represent potential leads in the ongoing search for novel alcohol abuse therapies.
dc.format.extent357 pages
dc.language.isoen
dc.publisherUniversity of Kansas
dc.rightsCopyright held by the author.
dc.subjectChemistry
dc.subjectPharmaceutical sciences
dc.subjectPharmacology
dc.subjectalcohol abuse
dc.subjectbiological probes
dc.subjectCNS disorders
dc.subjectKOP receptor
dc.subjectsalvinoirn A
dc.subjectsynthetic cannabinoids
dc.titleDesign and Synthesis of Novel CNS Biological Probes
dc.typeDissertation
dc.contributor.cmtememberBlagg, Brian S. J.
dc.contributor.cmtememberKrise, Jeffrey P
dc.contributor.cmtememberRaffery, Michael F
dc.contributor.cmtememberTunge, Jon A
dc.thesis.degreeDisciplineMedicinal Chemistry
dc.thesis.degreeLevelPh.D.
dc.provenance04/04/2017: The ETD release form is attached to this record as a license file.
kusw.bibid8086381
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record